Joseph Clay Thornton was named Chief Financial Officer of Clover Health Investments, Corp. /De. As of November 6, 2026, Clover Health Investments, Corp. /De has reported 5 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 1, 2026 to November 4, 2026, naming 1 appointment and 2 departures (Form 8-K, November 4, 2026).
Who owns Clover Health Investments Corp?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Clover Health Investments, Corp. /De? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Joseph Clay Thornton · Role: Chief Financial Officer · 8-K, 2026-11-04
- · In / out: Reported · Person: not named in the filing · 8-K/A, 2026-09-25
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-24
- · In / out: Out · Person: Brady Priest · Role: Chief Executive Officer · Effective: 2026-07-03 · 8-K, 2026-06-16
- · In / out: Out · Person: Peter Kuipers · Role: Chief Financial Officer · 8-K, 2026-04-01
Clover Health Investments, Corp. /De reported changes in 5 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-01 to 2026-11-04. They name 3 people, with 1 appointment and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Clover Health Investments, Corp. /De files it.
Also on the record for Clover Health Investments, Corp. /De
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G, by The Vanguard Group | 5.82% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G, by BlackRock, Inc. | 7.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Clover Health Investments, Corp. /De now and the warning signs.
Free to see. No signup.
Keep reading
More on Clover Health Investments, Corp. /De and the records around it.
Clover Health Investments, Corp. /De elsewhere on the record
Companies that share a holder
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Clover Health Investments, Corp. /De
Get an email when Clover Health Investments, Corp. /De files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Clover Health Investments, Corp. /De?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Clover Health Investments, Corp. /De: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Clover Health Investments, Corp. /De covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-04 | In | Chief Financial Officer | 8-K, 2026-11-04 | ||
| 2026-09-25 | Reported | not named in the filing | 8-K/A, 2026-09-25 | ||
| 2026-09-24 | Reported | not named in the filing | 8-K, 2026-09-24 | ||
| 2026-06-16 | Out | Chief Executive Officer | 2026-07-03 | 8-K, 2026-06-16 | |
| 2026-04-01 | Out | Chief Financial Officer | 8-K, 2026-04-01 |
Who leads Clover Health Investments, Corp. /De, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Joseph Clay Thornton, appointed (filed 2026-11-04).
- Chief Executive Officer: Brady Priest, departure reported, effective 2026-07-03 (filed 2026-06-16). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Clover Health Investments, Corp. /De: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Clover Health Investments, Corp. /De, with the record behind each one.
Find candidates like Chief Financial Officer at Clover Health Investments, Corp. /DeEvery change, in the filing's words
Appointed: Joseph Clay Thornton, Chief Financial Officer
On November 2, 2026, the Board of Directors of the Company appointed Joseph Clay Thornton, age 37, the Company's Interim Chief Financial Officer and principal financial officer, to serve as the Company's Chief Financial Officer on a permanent basis, and appointed Joseph Frank Oldakowski, age 44, the Company's Vice President, Controller and principal accounting officer, to serve as the Company's Chief Accounting Officer.
- The respective appointments are effective November 4, 2026.
- Since March 30, 2026, Mr. Thornton and Mr. Oldakowski have served as the Company's principal financial officer and principal accounting officer, respectively, and will continue to serve in such roles.
- Under the terms of his new employment agreement with the Company, effective November 4, 2026, Mr. Thornton will receive an annual base salary of $450,000, and the initial target amount for his annual cash incentive bonus will be up to 75% of his base salary.
- Subject to approval by the Board of Directors, its Talent and Compensation Committee or an authorized delegate, as applicable, he will also receive a promotional grant of restricted stock units ("RSUs") covering shares of the Company's Class A Common Stock with a grant date fair value of $1,500,000, to be granted on November 4, 2026 or as soon as practicable thereafter.
- The RSUs will vest and become payable as follows: 25% will vest on the first anniversary of the grant date, and the remainder will vest in twelve equal quarterly installments beginning on the date that is three months after the first anniversary of the grant date, in each case subject to Mr. Thornton's continued provision of services through each vesting date and any applicable vesting acceleration rights.
Reported
On September 22, 2026, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Senator Robert G. Torricelli to serve as a Class I director of the Board and Dr. Brian J. Miller, M.D., M.B.A., M.P.H. to serve as a Class III director of the Board.
- Senator Torricelli has been appointed to the Audit Committee of the Board and Dr. Miller has been appointed to the Clinical Committee of the Board.
- The appointments fill the Board's two previously disclosed vacancies and bring the Board to nine directors.
- Senator Torricelli is the founder of Rosemont Associates, a business strategy firm, which was founded in 2002, and a founder and partner of Woodrose Properties, a real estate development firm which was founded in 2003.
- He has served as a director of the Company's insurance subsidiaries since 2022 and as a director of Glassbridge Enterprises, Inc. since February 2017.
- Previously, he was executive vice president and chief operating officer of Aveta, Inc., a healthcare services company, from March 2007 to February 2012.
- Senator Torricelli represented New Jersey in the U.S. Senate from 1997 to 2003 and in the U.S. House of Representatives from 1983 to 1997.
- He holds a B.A. and J.D. from Rutgers University and a Master of Public Administration from Harvard University.
- Dr. Miller has extensive experience in clinical medicine, healthcare policy, regulation and health plan governance.
- Since September 2020, he has served as an Associate Professor of Medicine and Business (Courtesy) at Johns Hopkins University and practiced as a hospitalist at Johns Hopkins Hospital.
Reported
On September 22, 2026, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Senator Robert G. Torricelli to serve as a Class I director of the Board and Dr. Brian J. Miller, M.D., M.B.A., M.P.H. to serve as a Class III director of the Board.
- Senator Torricelli has been appointed to the Audit Committee of the Board and Dr. Miller has been appointed to the Clinical Committee of the Board.
- The appointments fill the Board's two previously disclosed vacancies and bring the Board to nine directors.
- Senator Torricelli is the founder of Rosemont Associates, a business strategy firm, which was founded in 2002, and a founder and partner of Woodrose Properties, a real estate development firm which was founded in 2003.
- He has served as a director of the Company's insurance subsidiaries since 2022 and as a director of Glassbridge Enterprises, Inc. since February 2017.
- Previously, he was executive vice president and chief operating officer of Aveta, Inc., a healthcare services company, from March 2007 to February 2012.
- Senator Torricelli represented New Jersey in the U.S. Senate from 1997 to 2003 and in the U.S. House of Representatives from 1983 to 1997.
- He holds a B.A. and J.D. from Rutgers University and a Master of Public Administration from Harvard University.
- Dr. Miller has extensive experience in clinical medicine, healthcare policy, regulation and health plan governance.
- Since September 2020, he has served as an Associate Professor of Medicine and Business (Courtesy) at Johns Hopkins University and practiced as a hospitalist at Johns Hopkins Hospital.
Departing: Brady Priest, Chief Executive Officer, effective 2026-07-03
On June 15, 2026, Brady Priest notified Clover Health Investments, Corp. (the "Company") of his decision to step down from his position as Chief Executive Officer of Clover Care Services, the Company's home-care business, effective as of July 3, 2026.
- In connection with Mr. Priest's departure, the Company has determined that it will not appoint a successor to that position.
- Instead, the responsibilities previously led by Mr. Priest will be reorganized and allocated among members of the Company's existing executive leadership team.
- The Company believes this structure will more closely integrate Clover Care Services with the Company's broader operations.
- Mr. Priest's departure was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- In some cases, you can identify forward looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "going to," "can," "could," "should," "would," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "outlook," "forecast," "guidance," "objective," "plan," "seek," "grow," "if," "continue" or the negative of these words or other similar terms or expressions that concern the Company's expectations, strategy, priorities, plans or intentions.
- These statements are based on current expectations, assumptions, and beliefs and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
Departing: Peter Kuipers, Chief Financial Officer
As part of this transition, effective immediately, Mr. Peter Kuipers has stepped down from his role as the Chief Financial Officer of the Company, including as principal financial officer and principal accounting officer, and the Board appointed Mr. Clay Thornton as the Interim Chief Financial Officer of the Company.
- Chief Financial Officer Transition On March 30, 2026, the board of directors (the "Board") of Clover Health Investments, Corp. (the "Company") approved a transition of the Chief Financial Officer role.
- Mr. Thornton, the current Chief Financial Officer of Clover Insurance Company, will also be serving as the Company's principal financial officer.
- In addition, Mr. Joseph (Joe) Oldakowski, Vice President of Finance and Controller of the Company, was appointed by the Board to serve as the Company's principal accounting officer, effective immediately.
- Mr. Kuipers will remain employed by the Company performing transition services and will continue to receive his current base salary and continued equity vesting until April 24, 2026.
- His departure does not reflect any disagreement between the Company and Mr. Kuipers on any matter relating to the Company's operations, policies or practices.
- Mr. Thornton, age 36, has served in his current role at the Company since February 2024.
- Prior to that, Mr. Thornton served as Vice President, Venture and PE Finance at Hunsicker from January 2023 to February 2024.
- From January 2022 to December 2022, Mr. Thornton served in financial services for Venture & PE Backed Companies at Venture First.
- From July 2021 to December 2021, Mr. Thornton served as Vice President - Strategy for Honest Health.
Tools for this story
Each opens in a new tab, filled in for Clover Health Investments, Corp. /De. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.